|Data presented at the 53rd annual meeting of the American College of Sports Medicine (ACSM)|
CVAC Systems Inc. (www.cvacsystems.com) announced today that data presented by Ronald K. Hetzler, Ph.D., FACSM, Associate Professor of Health, Exercise Science & Lifestyle Management in the Department of Kinesiology & Leisure Science at the University of Hawaii (Manoa), demonstrated a significant acclimation in elite athletes in exposures of one hour a day for five days a week. Dr. Hetzler presented the results at the 53rd annual meeting of the American College of Sports Medicine (ACSM).
"These data, collected in our laboratory at the University of Hawaii, achieved significance demonstrating that elite athletes using CVAC achieved high-altitude acclimatization in exposures of one hour a day five days a week," stated Dr. Hetzler, the principal investigator for the study.
"Because the exposure time was so short, these data suggest that athletes using CVAC do not have to trade off the benefits of high-altitude acclimation versus impairment of recovery," said Allen J. Ruszkowski, President and CEO of CVAC Systems. "Spending time at high altitude before training at low altitude is well-established to result in a marked improvement in athletic performance. Moreover, CVAC's unique potential to improve tissue oxygenation, enhance lymph, organ and glandular function, as well as reduce inflammation suggests that CVAC's use in therapeutic applications could be very broad once we obtain the necessary data and approvals."
CVAC Systems will be presenting on Thursday at 10:50 a.m. PDT, June 22, during Medtech Insight and Windhover Information's "In3 Medical Device Summit" conference, to be held June 21-23, 2006, at The Palace Hotel in San Francisco.
CVAC Systems is headquartered in Temecula, Calif. The Company is privately funded and is currently negotiating a strategic partnership in the physical therapy and rehabilitation sector. The Company seeks to place CVAC instruments at key luminary research sites for the development of performance enhancement and therapeutic health-related applications in several patent-pending applications. For these plans, the Company is seeking a first-round venture/institutional financing.
Please note: The information contained within this document is intended for prospective investors only, and is not intended for patients or health care providers. Any references to therapeutic applications are for discussion and investment purposes only.